These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38869974)

  • 1. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.
    Cai M; Liang L; Zhang J; Chen N; Huang W; Guo Y; Hong X; Lin L; Liu Y; Dan C; Deng H; Liu X; Zhou J; Chen Y; Chen H; Zhu K
    Int J Surg; 2024 Jun; ():. PubMed ID: 38869974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
    Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
    Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma.
    Huang J; Huang W; Zhan M; Guo Y; Liang L; Cai M; Lin L; He M; Lian H; Lu L; Zhu K
    J Hepatocell Carcinoma; 2021; 8():1445-1458. PubMed ID: 34858889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience.
    Zhao W; Liu C; Wu Y; Yao Z; Dou Q; Li W; Zhao X; Xia N
    Transl Cancer Res; 2024 May; 13(5):2315-2331. PubMed ID: 38881913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma.
    Liu B; Gao S; Guo J; Kou F; Liu S; Zhang X; Feng A; Wang X; Cao G; Chen H; Liu P; Xu H; Gao Q; Yang R; Xu L; Zhu X
    J Hepatocell Carcinoma; 2024; 11():477-488. PubMed ID: 38463543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
    Wu Z; Gao J; Zhuang W; Yang J; Guo W
    J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
    Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
    Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score-matching cohort study.
    Chen S; Yuan B; Yu W; Wang X; He C; Chen C
    J Surg Oncol; 2022 Dec; 126(7):1205-1214. PubMed ID: 35856502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis.
    Fan W; Zhu B; Yue S; Zheng X; Zou X; Li F; Qiao L; Wu Y; Xue M; Wang H; Tang Y; Li J
    Cancer Med; 2023 Jan; 12(1):61-72. PubMed ID: 35698292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.
    Chen B; Dai H; Yang J; Zhang G; Wen C; Xiang X; Lin R; Huang Y
    Curr Cancer Drug Targets; 2023; 23(7):564-571. PubMed ID: 36790005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A randomized clinical trial.
    Zhou TY; Tao GF; Zhou GH; Zhang YL; Zhu TY; Chen SQ; Wang HL; Wang BQ; Jing L; Chen F
    Int J Surg; 2024 May; ():. PubMed ID: 38775550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
    Kosaka Y; Kawaoka T; Aikata H; Suehiro Y; Yamaoka K; Ando Y; Namba M; Takeuchi Y; Fujii Y; Uchikawa S; Kodama K; Oya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Kimura T; Nagata Y; Chayama K
    Clin J Gastroenterol; 2020 Oct; 13(5):839-843. PubMed ID: 31974811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of raltitrexed-eluting CalliSpheres
    Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
    Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
    Chang X; Li X; Sun P; Li Z; Sun P; Ning S
    BMC Cancer; 2024 Apr; 24(1):480. PubMed ID: 38627684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.